Streetbeat News

Earnings

KNTE

Kinnate Biopharma reported Q3 losses of $(0.65) per share, beating the analyst consensus estimate of $(0.67) by 2.99 percent. This is a 7.14 percent increase over losses of $(0.70) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:37 pm

PHIO

Phio Pharmaceuticals Corp. has reported a Q3 earnings per share (EPS) of $(1.14).

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:37 pm

DNTH

Dianthus Therapeutics (NASDAQ:DNTH) reported Q3 losses of $(3.78) per share. However, the company's quarterly sales of $924.00 thousand beat the analyst consensus estimate of $500.00 thousand by 84.80 percent.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:37 pm

BW

Babcock & Wilcox Enterprises has projected its FY23 adjusted EBITDA to be between $85M and $90M, excluding the contributions from BrightLoop and ClimateBright.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:35 pm

KIQ

Kelso Technologies reported its Q3 earnings per share (EPS) at $0.00, up from $(0.01) year over year (YoY). The company's sales also increased to $3.14M from $2.71M YoY.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:35 pm

LVOX

LiveVox Holdings (NASDAQ:LVOX) reported Q3 losses of $(0.06) per share, missing the analyst consensus estimate of $(0.01) by 500%. The company also reported quarterly sales of $35.35 million, missing the analyst consensus estimate of $36.27 million by 2.53%. However, this represents a 0.28% increase over sales of $35.25 million from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:34 pm

AURA

Aura Biosciences (NASDAQ:AURA) reported Q3 losses of $(0.48) per share, beating the analyst consensus estimate of $(0.52) by 7.69 percent. This represents an 11.11 percent increase over losses of $(0.54) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:33 pm

BW

Babcock & Wilcox Enterprises reported Q3 2023 earnings per share (EPS) of $(0.18), down from $(0.15) year over year. The company's revenue of $239.4M missed the estimated $289.450M.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:33 pm

ITI

Iteris Inc. anticipates its Q3 total revenue to be between $41M and $43M, representing a year-over-year growth of 3% at the mid-point of the guidance range.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:33 pm

ANTX

AN2 Therapeutics (NASDAQ:ANTX) reported Q3 losses of $(0.65) per share, beating the analyst consensus estimate of $(0.70) by 7.14%. However, this represents a 10.17% increase in losses compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:32 pm